Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with FLAG for relapsed/refractory or induction-failure acute myeloid leukemia
ChiCTR1800015871Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Apr 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat, fludarabine, cytarabine and filgrastim in acute myeloid leukemia (AML), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Complete remission rate. Started Apr 2018; status: recruiting.
02
Drugs
tucidinostatfludarabinecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800015871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015871.